GMP IPO
📋 Filings Intelligence
About Contact
LIVE - Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement - financial results, order wins, dividends, mergers and more. Updated live.

-
Filed today
-
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings -

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Evonile Pharma Ltd

Evonile Pharma Q2 FY27: Total Financial Indebtedness at INR 800

RESULTS ● No Immediate Change LOW RISK
📅 Filed on BSE: 03 Nov 2026, 07:23 PM IST  ·  BSE ID: 38ee6ffe-dbc8-4c58-a57e-40b3b3f96b0c
View Original BSE Filing (PDF)
💡
In Simple Terms
Evonile Pharma reported its financial standing for the quarter, showing INR 800 in total debt with no payment defaults.
🤖 AI Summary
  • Evonile Pharma's total financial indebtedness is reported as INR 800 as of September 30, 2026.
  • The company has Nil default on loans and revolving facilities from banks/financial institutions.
  • Related party transactions totaled INR 126.09 during Q2 FY27 (QTD Sep'26).
  • Half-year (YTD Sep'26) related party transactions amounted to INR 593.83.
  • The filing includes unaudited financial statements for the quarter and half year ended September 30, 2026.
🔢 Key Numbers - exact figures from BSE filing, not rounded
Total financial indebtedness of the listed entity (INR)
800
Loans/revolving facilities like cash credit from banks/financial institutions outstanding (INR)
800
Default on loans/revolving facilities (INR)
Nil
Total related party transactions QTD Sep'26 (INR)
126.09
Total related party transactions YTD Sep'26 (INR)
593.83
🏢 How This Affects the Company
💰
Financial Impact
The company's financial indebtedness is stated as INR 800, with no reported defaults on its loans from banks or financial institutions.
⚠️
Risk Impact
The absence of outstanding defaults on loans from banks and financial institutions indicates no immediate liquidity risk related to current debt obligations.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required by shareholders based on this filing.
👤
Who Is Affected
Shareholders are informed about the company's debt status, which indicates a total financial indebtedness of INR 800 and the absence of any defaults on bank loans.
🔍
Management Signal
The disclosure of nil defaults on outstanding loans reflects management's adherence to debt obligations as of the reporting date.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List - track these upcoming events
Q3 FY27 financial results – to assess revenue and profitability.
Future disclosures on total financial indebtedness for any changes.
Updates on related party transactions in subsequent half-yearly filings.
LOW RISK No defaults on debt and stable financial indebtedness reported.
💡 Investor Takeaway
Evonile Pharma Ltd.'s Q2 FY27 filing confirms total financial indebtedness of INR 800 as of September 30, 2026, with no outstanding defaults on bank loans. Related party transactions amounted to INR 126.09 for QTD Sep'26 and INR 593.83 for YTD Sep'26.
⚖️ Strengths & Concerns

✅ Positives

  • Nil default on loans and revolving facilities from banks/financial institutions as of September 30, 2026.
  • No outstanding unlisted debt securities like NCDs and NCRPS reported in the filing.

⚠️ Concerns

  • The filing does not provide detailed financial performance metrics like revenue or profit figures for the quarter.
  • The filing is an Integrated Filing (Financial) and primarily focuses on debt and related party transactions, lacking broader financial performance data.
📅 Company Track Record
Evonile Pharma Limited, formerly Novartis India Limited, reported NIL total financial indebtedness for Q1 FY27 and FY26 in prior filings (July 2026 and May 2026). This filing now reports INR 800 in total financial indebtedness as of Q2 FY27.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What is Evonile Pharma's total financial indebtedness as of September 30, 2026?
Evonile Pharma's total financial indebtedness, including short-term and long-term debt, is INR 800 as of September 30, 2026.
Did Evonile Pharma have any defaults on loans in Q2 FY27?
No, Evonile Pharma reported Nil default on loans/revolving facilities from banks/financial institutions as of September 30, 2026.
What was the total value of related party transactions for Evonile Pharma in Q2 FY27?
The total value of related party transactions for Evonile Pharma during the reporting period QTD Sep'26 (Q2 FY27) was INR 126.09.
What was the half-year total for related party transactions for Evonile Pharma (YTD Sep'26)?
The total value of related party transactions for the half year ended YTD Sep'26 was INR 593.83.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again - explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only - Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector - takes 5 seconds.